Tyrvaya (Varenicline Tartrate) Patent Expiration, LOE Window & CMS Spending

Tyrvaya (Varenicline Tartrate) by Oyster Point: FDA Orange Book LOE 2035-10-19, 20 AB generics, $79.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOyster Point
FDA Application & PathwayN213978 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-10-19
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors20
2024 CMS Total Public Spend$79.1M
2024 Medicare Part D Spend$71.7M
2024 Medicaid Spend$7.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel